查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1352919

全球慢性阻塞性肺病 (COPD) 治疗市场研究报告 - 2023 年至 2030 年行业分析、规模、份额、成长、趋势和预测

Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030
出版日期: | 出版商: Value Market Research | 英文 168 Pages | 商品交期: 最快1-2个工作天内

价格

全球慢性阻塞性肺病（COPD）治疗市场的需求预计将从2022年的230.2亿美元增加到2030年的近384.4亿美元，2023-2030年研究期间的复合年增长率为6.62%。

肺部发炎会导致慢性阻塞性肺病（COPD），进而阻碍肺部气流。这是一种慢性疾病，症状包括喘息、产生黏液和呼吸困难。肺部疾病包括难治性气喘、肺气肿和慢性支气管炎。慢性阻塞性肺病主要是由吸烟、空气污染、二手烟、α-1缺乏相关肺气肿（慢性阻塞性肺病的一种罕见形式）和其他因素引起的。在某些情况下可以避免併发症，在其他情况下可以减少疾病进展。这些措施可能包括戒烟、依照指示服用处方药，以及接种流感、肺炎等感染疫苗，以预防相关的併发症。

市场动态：

由于三联疗法和数位吸入器选项的日益普及，慢性阻塞性肺病（COPD）治疗市场的市场参与者预计在研究期间需求将会增加。慢性阻塞性肺病的危险因子不断增加，使得这种疾病相当普遍，从而迫使政府和医疗机构提供更好的治疗。此外，公众对慢性阻塞性肺病预防的认识有所提高，预计将推动该市场的发展。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具还对全球慢性阻塞性肺病 (COPD) 治疗市场的各个细分市场进行了包容性评估。慢性阻塞性肺病 (COPD) 治疗产业的成长和趋势为本研究提供了整体方法。

区域分析：

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲的慢性阻塞性肺病（COPD）治疗市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。慢性阻塞性肺病（COPD）治疗市场的主要参与者包括Almirall、阿斯特捷利康、勃林格殷格翰国际有限公司、CHIESI Farmaceutici SpA、F. Hoffmann-La Roche Ltd.、葛兰素史克公司、Kyowa Hakko Kirin、Mylan NV、诺华公司、 Orion Corporation、赛诺菲、Sunovion Pharmaceuticals Inc. （住友大日本製药有限公司）、Teva Pharmaceutical Industries Ltd.、Theravance Biopharma、Verona Pharmaceuticals。本节包含竞争格局的整体视图，包括各种策略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

目录

第一章：前言

  • 报告说明
    • 客观的
    • 目标受众
    • 独特的销售主张 (USP) 和产品
  • 研究范围
  • 研究方法论
    • 市场研究过程
    • 市场研究方法论

第 2 章：执行摘要

  • 市集亮点
  • 全球市场概况

第 3 章：慢性阻塞性肺病 (COPD) 治疗 - 产业分析

  • 简介 - 市场动态
  • 市场驱动因素
  • 市场限制
  • 机会
  • 产业动态
  • 波特五力分析
  • 市场吸引力分析
    • 按药品类别分類的市场吸引力分析
    • 按类型分類的市场吸引力分析
    • 按分销管道分類的市场吸引力分析
    • 市场吸引力分析：按地区

第 4 章：价值链分析

  • 价值链分析
  • 原料分析
    • 原料清单
    • 原料厂商清单
    • 主要原物料价格走势
  • 潜在买家名单
  • 行销管道
    • 直效行销
    • 间接行销
    • 行销通路发展趋势

第 5 章：COVID-19 爆发的影响分析

第 6 章：全球慢性阻塞性肺病 (COPD) 治疗市场分析：按药物类别

  • 按药物类别概述
  • 历史和预测数据
  • 按药物类别分析
  • 联合疗法
  • 支气管扩张剂
  • 皮质类固醇
  • 4 型磷酸二酯酶抑制剂
  • 黏液动力学
  • 其他的

第 7 章：全球慢性阻塞性肺病 (COPD) 治疗市场分析：按类型

  • 按类型概述
  • 历史和预测数据
  • 按类型分析
  • 慢性支气管炎
  • 气肿

第 8 章：全球慢性阻塞性肺病 (COPD) 治疗市场销售分析：按分销管道

  • 按分销管道分類的概览
  • 历史和预测数据
  • 按分销管道分析
  • 医院药房
  • 零售药局
  • 网路药局

第 9 章：全球慢性阻塞性肺病 (COPD) 治疗市场销售分析：按地理位置

  • 区域展望销售分析
  • 简介 销售分析
  • 北美销售分析
    • 概述、历史和预测销售分析
    • 北美按细分市场销售分析
    • 北美按国家销售分析
    • 美国销售分析
    • 加拿大销售分析
    • 墨西哥销售分析
  • 欧洲销售分析
    • 概述、历史和预测销售分析
    • 欧洲按细分市场销售分析
    • 欧洲按国家销售分析
    • 英国销售分析
    • 法国销售分析
    • 德国销售分析
    • 义大利销售分析
    • 俄罗斯销售分析
    • 欧洲其他地区销售分析
  • 亚太地区销售分析
    • 概述、历史和预测销售分析
    • 亚太地区按细分市场销售分析
    • 亚太地区国家/地区销售分析
    • 中国销售分析
    • 印度销售分析
    • 日本销售分析
    • 韩国销售分析
    • 澳洲销售分析
    • 亚太地区其他地区销售分析
  • 拉丁美洲销售分析
    • 概述、历史和预测销售分析
    • 拉丁美洲按细分市场销售分析
    • 拉丁美洲按国家销售分析
    • 巴西销售分析
    • 阿根廷销售分析
    • 秘鲁销售分析
    • 智利销售分析
    • 拉丁美洲其他地区销售分析
  • 中东和非洲销售分析
    • 概述、历史和预测销售分析
    • 中东和非洲按细分市场销售分析
    • 中东和非洲国家销售分析
    • 沙乌地阿拉伯销售分析
    • 阿联酋销售分析
    • 以色列销售分析
    • 南非销售分析
    • 中东其他地区和非洲销售分析

第 10 章：慢性阻塞性肺病 (COPD) 治疗公司的竞争格局

  • 慢性阻塞性肺病（COPD）治疗市场竞争
  • 伙伴关係/协作/协议
  • 併购
  • 新产品发布
  • 其他发展

第 11 章：公司简介

  • 十大公司股票分析
  • 市场集中度
  • Almirall
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • AstraZeneca
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Boehringer Ingelheim International GmbH
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • CHIESI Farmaceutici SpA
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • F. Hoffmann-La Roche Ltd.
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • GlaxoSmithKline plc
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Kyowa Hakko Kirin
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Mylan NV
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Novartis AG
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Orion Corporation
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Sanofi
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Sunovion PharmaceuticalsInc. (Sumitomo Dainippon Pharma Co. Ltd.)
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Teva Pharmaceutical Industries Ltd.
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Theravance Biopharma
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Verona Pharmaceuticals
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展

注意 - 在公司概况中，财务详细资讯和近期发展视情况而定，或者如果是私人公司，则可能不包括在内

Product Code: VMR11218849

The global demand for Chronic Obstructive Pulmonary Disease (COPD) Treatment Market is presumed to reach the market size of nearly USD 38.44 BN by 2030 from USD 23.02 BN in 2022 with a CAGR of 6.62% under the study period 2023 - 2030.

Inflammation of the lungs contributes to chronic obstructive pulmonary disease (COPD), which blocks airflow from the lungs. It is a chronic ailment with symptoms that include wheezing, mucous production, and trouble breathing. The lung condition comprises refractory asthma, emphysema, and chronic bronchitis. COPD is mostly brought on by smoking, air pollution, secondhand smoke, alpha-1 deficiency-related emphysema (a rare form of COPD), and other factors. Complications can be avoided in some situations, and illness progression can be reduced in others. These may include giving up smoking, taking prescribed medications as directed, and being vaccinated against infections like the flu, pneumonia, and others to prevent associated co-morbidities.

MARKET DYNAMICS:

Due to the growing popularity of triple therapy treatment options and digital inhaler options, market players within the chronic obstructive pulmonary disease (COPD) treatment market is projected to experience an increase in demand during the study period. Increasing risk factors for developing chronic obstructive pulmonary disease have made the condition rather common, thus forcing government and healthcare institutions to provide better treatment. Additionally, there has been an increase in public awareness of COPD prevention, which is anticipated to boost this market.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of chronic obstructive pulmonary disease (copd) treatment. The growth and trends of chronic obstructive pulmonary disease (copd) treatment industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the chronic obstructive pulmonary disease (copd) treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class

  • Combination Therapy
  • Bronchodilators
  • Corticosteroids
  • Phosphodiesterase Type 4 Inhibitor
  • Mucokinetics
  • Others

By Type

  • Chronic Bronchitis
  • Emphysema

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Chronic Obstructive Pulmonary Disease (COPD) Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the chronic obstructive pulmonary disease (copd) treatment market include Almirall, AstraZeneca, Boehringer Ingelheim International GmbH, CHIESI Farmaceutici S.p.A., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Kyowa Hakko Kirin, Mylan N.V., Novartis AG, Orion Corporation, Sanofi, Sunovion PharmaceuticalsInc. (Sumitomo Dainippon Pharma Co., Ltd.), Teva Pharmaceutical Industries Ltd., Theravance Biopharma, Verona Pharmaceuticals. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

  • 1.1. Report Description
    • 1.1.1. Objective
    • 1.1.2. Target Audience
    • 1.1.3. Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3 . CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Drug Class
    • 3.7.2 Market Attractiveness Analysis By Type
    • 3.7.3 Market Attractiveness Analysis By Distribution Channel
    • 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1. List of Raw Materials
    • 4.2.2. Raw Material Manufactures List
    • 4.2.3. Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1. Direct Marketing
    • 4.4.2. Indirect Marketing
    • 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT MARKET ANALYSIS BY DRUG CLASS

  • 6.1 Overview by Drug Class
  • 6.2 Historical and Forecast Data
  • 6.3 Analysis by Drug Class
  • 6.4 Combination Therapy Historic and Forecast Sales by Regions
  • 6.5 Bronchodilators Historic and Forecast Sales by Regions
  • 6.6 Corticosteroids Historic and Forecast Sales by Regions
  • 6.7 Phosphodiesterase Type 4 Inhibitor Historic and Forecast Sales by Regions
  • 6.8 Mucokinetics Historic and Forecast Sales by Regions
  • 6.9 Others Historic and Forecast Sales by Regions

7 . GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT MARKET ANALYSIS BY TYPE

  • 7.1 Overview by Type
  • 7.2 Historical and Forecast Data
  • 7.3 Analysis by Type
  • 7.4 Chronic Bronchitis Historic and Forecast Sales by Regions
  • 7.5 Emphysema Historic and Forecast Sales by Regions

8 . GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT MARKET SALES ANALYSIS BY DISTRIBUTION CHANNEL

  • 8.1 Overview by Distribution Channel
  • 8.2 Historical and Forecast Data
  • 8.3 Analysis by Distribution Channel
  • 8.4 Hospital Pharmacies Historic and Forecast Sales by Regions
  • 8.5 Retail Pharmacies Historic and Forecast Sales by Regions
  • 8.6 Online Pharmacies Historic and Forecast Sales by Regions

9 . GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT MARKET SALES ANALYSIS BY GEOGRAPHY

  • 9.1. Regional Outlook Sales Analysis
  • 9.2. Introduction Sales Analysis
  • 9.3. North America Sales Analysis
    • 9.3.1. Overview, Historic and Forecast Sales Analysis
    • 9.3.2. North America By Segment Sales Analysis
    • 9.3.3. North America By Country Sales Analysis
    • 9.3.4. United State Sales Analysis
    • 9.3.5. Canada Sales Analysis
    • 9.3.6. Mexico Sales Analysis
  • 9.4. Europe Sales Analysis
    • 9.4.1. Overview, Historic and Forecast Sales Analysis
    • 9.4.2. Europe by Segment Sales Analysis
    • 9.4.3. Europe by Country Sales Analysis
    • 9.4.4. United Kingdom Sales Analysis
    • 9.4.5. France Sales Analysis
    • 9.4.6. Germany Sales Analysis
    • 9.4.7. Italy Sales Analysis
    • 9.4.8. Russia Sales Analysis
    • 9.4.9. Rest Of Europe Sales Analysis
  • 9.5. Asia Pacific Sales Analysis
    • 9.5.1. Overview, Historic and Forecast Sales Analysis
    • 9.5.2. Asia Pacific by Segment Sales Analysis
    • 9.5.3. Asia Pacific by Country Sales Analysis
    • 9.5.4. China Sales Analysis
    • 9.5.5. India Sales Analysis
    • 9.5.6. Japan Sales Analysis
    • 9.5.7. South Korea Sales Analysis
    • 9.5.8. Australia Sales Analysis
    • 9.5.9. Rest Of Asia Pacific Sales Analysis
  • 9.6. Latin America Sales Analysis
    • 9.6.1. Overview, Historic and Forecast Sales Analysis
    • 9.6.2. Latin America by Segment Sales Analysis
    • 9.6.3. Latin America by Country Sales Analysis
    • 9.6.4. Brazil Sales Analysis
    • 9.6.5. Argentina Sales Analysis
    • 9.6.6. Peru Sales Analysis
    • 9.6.7. Chile Sales Analysis
    • 9.6.8. Rest of Latin America Sales Analysis
  • 9.7. Middle East & Africa Sales Analysis
    • 9.7.1. Overview, Historic and Forecast Sales Analysis
    • 9.7.2. Middle East & Africa by Segment Sales Analysis
    • 9.7.3. Middle East & Africa by Country Sales Analysis
    • 9.7.4. Saudi Arabia Sales Analysis
    • 9.7.5. UAE Sales Analysis
    • 9.7.6. Israel Sales Analysis
    • 9.7.7. South Africa Sales Analysis
    • 9.7.8. Rest Of Middle East And Africa Sales Analysis

10 . COMPETITIVE LANDSCAPE OF THE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT COMPANIES

  • 10.1. Chronic Obstructive Pulmonary Disease (Copd) Treatment Market Competition
  • 10.2. Partnership/Collaboration/Agreement
  • 10.3. Merger And Acquisitions
  • 10.4. New Product Launch
  • 10.5. Other Developments

11 . COMPANY PROFILES OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT INDUSTRY

  • 11.1. Top 10 Company Share Analysis
  • 11.2. Market Concentration Rate
  • 11.3. Almirall
    • 11.3.1. Company Overview
    • 11.3.2. Company Revenue
    • 11.3.3. Products
    • 11.3.4. Recent Developments
  • 11.4. AstraZeneca
    • 11.4.1. Company Overview
    • 11.4.2. Company Revenue
    • 11.4.3. Products
    • 11.4.4. Recent Developments
  • 11.5. Boehringer Ingelheim International GmbH
    • 11.5.1. Company Overview
    • 11.5.2. Company Revenue
    • 11.5.3. Products
    • 11.5.4. Recent Developments
  • 11.6. CHIESI Farmaceutici S.p.A.
    • 11.6.1. Company Overview
    • 11.6.2. Company Revenue
    • 11.6.3. Products
    • 11.6.4. Recent Developments
  • 11.7. F. Hoffmann-La Roche Ltd.
    • 11.7.1. Company Overview
    • 11.7.2. Company Revenue
    • 11.7.3. Products
    • 11.7.4. Recent Developments
  • 11.8. GlaxoSmithKline plc
    • 11.8.1. Company Overview
    • 11.8.2. Company Revenue
    • 11.8.3. Products
    • 11.8.4. Recent Developments
  • 11.9. Kyowa Hakko Kirin
    • 11.9.1. Company Overview
    • 11.9.2. Company Revenue
    • 11.9.3. Products
    • 11.9.4. Recent Developments
  • 11.10. Mylan N.V.
    • 11.10.1. Company Overview
    • 11.10.2. Company Revenue
    • 11.10.3. Products
    • 11.10.4. Recent Developments
  • 11.11. Novartis AG
    • 11.11.1. Company Overview
    • 11.11.2. Company Revenue
    • 11.11.3. Products
    • 11.11.4. Recent Developments
  • 11.12. Orion Corporation
    • 11.12.1. Company Overview
    • 11.12.2. Company Revenue
    • 11.12.3. Products
    • 11.12.4. Recent Developments
  • 11.13. Sanofi
    • 11.13.1. Company Overview
    • 11.13.2. Company Revenue
    • 11.13.3. Products
    • 11.13.4. Recent Developments
  • 11.14. Sunovion PharmaceuticalsInc. (Sumitomo Dainippon Pharma Co. Ltd.)
    • 11.14.1. Company Overview
    • 11.14.2. Company Revenue
    • 11.14.3. Products
    • 11.14.4. Recent Developments
  • 11.15. Teva Pharmaceutical Industries Ltd.
    • 11.15.1. Company Overview
    • 11.15.2. Company Revenue
    • 11.15.3. Products
    • 11.15.4. Recent Developments
  • 11.16. Theravance Biopharma
    • 11.16.1. Company Overview
    • 11.16.2. Company Revenue
    • 11.16.3. Products
    • 11.16.4. Recent Developments
  • 11.17. Verona Pharmaceuticals
    • 11.17.1. Company Overview
    • 11.17.2. Company Revenue
    • 11.17.3. Products
    • 11.17.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

LIST OF TABLES

  • Market Snapshot
  • Drivers : Impact Analysis
  • Restraints : Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • List of Potential Buyers
  • Analysis by Drug Class (USD MN)
  • Combination Therapy Market Sales by Geography (USD MN)
  • Bronchodilators Market Sales by Geography (USD MN)
  • Corticosteroids Market Sales by Geography (USD MN)
  • Phosphodiesterase Type 4 Inhibitor Market Sales by Geography (USD MN)
  • Mucokinetics Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Analysis Market by Type (USD MN)
  • Chronic Bronchitis Market Sales by Geography (USD MN)
  • Emphysema Market Sales by Geography (USD MN)
  • Analysis by Distribution Channel (USD MN)
  • Hospital Pharmacies Market Sales by Geography (USD MN)
  • Retail Pharmacies Market Sales by Geography (USD MN)
  • Online Pharmacies Market Sales by Geography (USD MN)
  • Global Chronic Obstructive Pulmonary Disease (Copd) Treatment Market Sales by Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United State Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate by Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Chronic Obstructive Pulmonary Disease (Copd) Treatment Report
  • Market Research Process
  • Market Research Methodology
  • Global Chronic Obstructive Pulmonary Disease (Copd) Treatment Market Size, by Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis by Drug Class
  • Market Attractiveness Analysis by Type
  • Market Attractiveness Analysis by Distribution Channel
  • Market Attractiveness Analysis by Region
  • Value Chain Analysis
  • Global Market Analysis by Drug Class (USD MN)
  • Combination Therapy Market Sales by Geography (USD MN)
  • Bronchodilators Market Sales by Geography (USD MN)
  • Corticosteroids Market Sales by Geography (USD MN)
  • Phosphodiesterase Type 4 Inhibitor Market Sales by Geography (USD MN)
  • Mucokinetics Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Global Market Analysis by Type (USD MN)
  • Chronic Bronchitis Market Sales by Geography (USD MN)
  • Emphysema Market Sales by Geography (USD MN)
  • Global Market Analysis by Distribution Channel (USD MN)
  • Hospital Pharmacies Market Sales by Geography (USD MN)
  • Retail Pharmacies Market Sales by Geography (USD MN)
  • Online Pharmacies Market Sales by Geography (USD MN)
  • Global Market by Revenue
  • North America Market by Revenue
  • Europe Market by Revenue
  • Asia Pacific Market by Revenue
  • Latin America Market by Revenue
  • Middle East & Africa Market by Revenue
  • Recent Development in Industry
  • Top Company Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.